Tagworks Pharmaceuticals BV
The primary objectives of this study are to evaluate the safety and tolerability of TGW101 and determine the recommended dosing regimen(s) for further study. The secondary objectives are to assess pharmacokinetics and preliminary antitumor activity.
Inclusion Criteria: 1. Written informed consent prior to any study procedures. 2. Males or females 18 years or older. 3. Histologically or cytologically confirmed diagnosis of a solid tumor malignancy listed below and have evidence of disease progression on or after (within 3 months of discontinuation) the most recent treatment regimen: 1. Endometrial cancer. 2. Esophageal, adenocarcinoma only. 3. Gastric/gastroesophageal junction (GEJ). 4. Non-small cell lung cancer, adenocarcinoma only. 5. Ovarian. 4. Refractory disease, intolerance to, or documented refusal of available sta…
TGW101 is a combination product comprising a chemically cleavable diabody drug conjugate (TGW101-ADC) and a corresponding small molecule chemical trigger (TRG001) administered separately.